A let-7 microRNA polymorphism in the KRAS 3′-UTR is prognostic in oropharyngeal cancer

Ruyck, Kim De; Duprez, Frédéric; Ferdinande, Liesbeth; Mbah, Chamberlain; Rios-Velazquez, Emmanuel; Hoebers, Frank; Praet, Marleen; Deron, Philippe; Bonte, Katrien; Speel, Ernst‐Jan M.; Libbrecht, Louis; Neve, Wilfried De; Lambin, Philippe; Thierens, Hubert

doi:10.1016/j.canep.2014.07.008

Cited by 21 publications

(17 citation statements)

References 35 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De Ruyck et al found that miRNA-let-7 polymorphisms in the KRAS 3′-UTR are a prognostic factor of oropharyngeal cancer (40). Another study showed that miR-146aG>C and miR-196a2C>T polymorphisms were associated with the risk of hepatocellular carcinoma (HCC) in patients in China, especially in patients with hepatitis B virus infection (41).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA gene polymorphisms and the risk of colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study was carried out to demonstrate the epidemiological value of microRNA (miRNA) in colorectal cancer (CRC) by investigating the association between miRNA gene polymorphisms and the susceptibility to CRC. Multiple meta-analyses of reported data were conducted, and odds ratio values and 95% confidence intervals were used to assess these associations. Stata 11.0 software was used to analyze the data and the modified Jadad quality score was employed to evaluate the quality of the retrieved studies. We retrieved 38 studies on the association between miRNA polymorphisms and risk of CRC, however only 15 met the requirements of the inclusion criteria. In conclusion, we identified a variety of miRNAs (miRNA-let-7, miR-34b/c, miR-146a, miR-603 and miR-149) gene polymorphisms that are associated with susceptibility to CRC. However, some miRNAs (miR-192a, miR-608 and miR-27a) are associated with CRC, but not susceptibility to CRC. The results have limitations given the relatively low number of studies available. Therefore, it is necessary to collect data from large sample-size studies to further validate the results.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA gene polymorphisms and the risk of colorectal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In fact, mutations in SMC1B have been recently identified in urothelial bladder cancer 51 and the Catalogue Of Somatic Mutation In Cancer database (COSMIC, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic) contains 163 unique mutations in SMC1B . In addition, polymorphisms in the SMC1B -binding site for miRNA are associated with early-stage head and neck cancer 52 and oropharyngeal cancer 53 . Since we found that SMC1B silencing led to gene expression dysregulation, it is plausible cohesin-SMC1B deregulation by mutation or epimutation may provide a potential source of destabilizing changes for allowing the transformation of a normal somatic cell into a cancer cell.…”

Section: Discussionmentioning

confidence: 99%

SMC1B is present in mammalian somatic cells and interacts with mitotic cohesin proteins

Mannini

Cucco

Quarantotti

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Cohesin is an evolutionarily conserved protein complex that plays a role in many biological processes: it ensures faithful chromosome segregation, regulates gene expression and preserves genome stability. In mammalian cells, the mitotic cohesin complex consists of two structural maintenance of chromosome proteins, SMC1A and SMC3, the kleisin protein RAD21 and a fourth subunit either STAG1 or STAG2. Meiotic paralogs in mammals were reported for SMC1A, RAD21 and STAG1/STAG2 and are called SMC1B, REC8 and STAG3 respectively. It is believed that SMC1B is only a meiotic-specific cohesin member, required for sister chromatid pairing and for preventing telomere shortening. Here we show that SMC1B is also expressed in somatic mammalian cells and is a member of a mitotic cohesin complex. In addition, SMC1B safeguards genome stability following irradiation whereas its ablation has no effect on chromosome segregation. Finally, unexpectedly SMC1B depletion impairs gene transcription, particularly at genes mapping to clusters such as HOX and PCDHB. Genome-wide analyses show that cluster genes changing in expression are enriched for cohesin-SMC1B binding.

show abstract

“…The LCS6 (Let-7 Complementary Sites 6) SNP (rs61764370) has been associated with an increased risk of lung cancer among people with a moderate smoking history [52]. This LCS6 SNP was also described as a biomarker of cancer treatment response in oral cancer [53, 54] and colorectal cancer [55, 56]. Finally, LCS6 SNP predicted improved response to anti-EGFR monoclonal antibody monotherapy in patients with metastatic colorectal cancer [57].…”

Section: Mirnas Targeting Krasmentioning

confidence: 99%

RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action

2015

View full text Add to dashboard Cite

The highly conserved RAS-mitogen activated protein kinase (MAPK) signaling pathway is involved in a wide range of cellular processes including differentiation, proliferation, and survival. Somatic mutations in genes encoding RAS-MAPK components frequently occur in many tumors, making the RAS-MAPK a critical pathway in human cancer. Since the pioneering study reporting that let-7 miRNA acted as tumor suppressor by repressing the RAS oncogene, growing evidence has suggested the importance of miRNAs targeting the RAS-MAPK in oncogenesis. MiRNAs alterations in human cancers may act as a rheostat of the oncogenic RAS signal that is often amplified as cancers progress. However, specific mechanisms leading to miRNAs deregulation and their functional consequences in cancer are far from being fully elucidated. In this review, we provide an experimental-validated map of RAS-MAPK oncomiRs and tumor suppressor miRNAs from transmembrane receptor to downstream ERK proteins. MiRNAs could be further considered as potential genetic biomarkers for diagnosis, prognosis, or therapeutic purpose.

show abstract

A let-7 microRNA polymorphism in the KRAS 3′-UTR is prognostic in oropharyngeal cancer

Abstract: Our results demonstrate that OPSCC patients with the KRAS-LCS6 variant have a better outcome and suggest that this variant may be used as a prognostic biomarker for OPSCC.

Cited by 21 publications

References 35 publications

MicroRNA gene polymorphisms and the risk of colorectal cancer

MicroRNA gene polymorphisms and the risk of colorectal cancer

SMC1B is present in mammalian somatic cells and interacts with mitotic cohesin proteins

RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action

Contact Info

Product

Resources

About